Executive Voice: He's raised $600M+ to build his gene therapy biotech in RTP
Bringing new gene therapies to the market is a costly and difficult process. But Shankar Ramaswamy and Kriya Therapeutics are trying to reshape the formula.
Bringing new gene therapies to the market is a costly and difficult process. But Shankar Ramaswamy and Kriya Therapeutics are trying to reshape the formula.